European regulators to review tepotinib for treatment of advanced non-small cell lung cancer (NSCLC) in adults harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations

Tepotinib is a highly selective oral MET inhibitor administered once daily, which has shown promise in the Phase II VISION study, which achieved the primary endpoint of objective response among patients with at least nine months' follow-up.

PharmaTimes